User login
Key clinical point: Trastuzumab deruxtecan demonstrated superior survival outcomes compared with trastuzumab emtansine in the second-line setting and also had a manageable safety profile in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC).
Major finding: Trastuzumab deruxtecan vs trastuzumab emtansine resulted in a ~36% reduction in the risk for death (hazard ratio 0.64; P = .0037) and the longest reported improvement in progression-free survival (28.8 months vs 6.8 months; nominal P < .0001). The rate of grade ≥3 adverse events was similar with trastuzumab deruxtecan vs trastuzumab emtansine (56% vs 52%).
Study details: Findings are from the phase 3, DESTINY-Breast03 trial including 524 patients with HER2+ metastatic BC who had progressed during or after treatment with trastuzumab and a taxane and were randomly assigned to receive trastuzumab deruxtecan or trastuzumab emtansine.
Disclosures: This study was funded by Daiichi Sankyo and AstraZeneca. Four authors declared being employees or stockholders of Daiichi Sankyo, and the other authors reported ties with various sources, including Daiichi Sankyo and AstraZeneca.
Source: Hurvitz SA et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2022 (Dec 7). Doi: 10.1016/S0140-6736(22)02420-5
Key clinical point: Trastuzumab deruxtecan demonstrated superior survival outcomes compared with trastuzumab emtansine in the second-line setting and also had a manageable safety profile in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC).
Major finding: Trastuzumab deruxtecan vs trastuzumab emtansine resulted in a ~36% reduction in the risk for death (hazard ratio 0.64; P = .0037) and the longest reported improvement in progression-free survival (28.8 months vs 6.8 months; nominal P < .0001). The rate of grade ≥3 adverse events was similar with trastuzumab deruxtecan vs trastuzumab emtansine (56% vs 52%).
Study details: Findings are from the phase 3, DESTINY-Breast03 trial including 524 patients with HER2+ metastatic BC who had progressed during or after treatment with trastuzumab and a taxane and were randomly assigned to receive trastuzumab deruxtecan or trastuzumab emtansine.
Disclosures: This study was funded by Daiichi Sankyo and AstraZeneca. Four authors declared being employees or stockholders of Daiichi Sankyo, and the other authors reported ties with various sources, including Daiichi Sankyo and AstraZeneca.
Source: Hurvitz SA et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2022 (Dec 7). Doi: 10.1016/S0140-6736(22)02420-5
Key clinical point: Trastuzumab deruxtecan demonstrated superior survival outcomes compared with trastuzumab emtansine in the second-line setting and also had a manageable safety profile in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC).
Major finding: Trastuzumab deruxtecan vs trastuzumab emtansine resulted in a ~36% reduction in the risk for death (hazard ratio 0.64; P = .0037) and the longest reported improvement in progression-free survival (28.8 months vs 6.8 months; nominal P < .0001). The rate of grade ≥3 adverse events was similar with trastuzumab deruxtecan vs trastuzumab emtansine (56% vs 52%).
Study details: Findings are from the phase 3, DESTINY-Breast03 trial including 524 patients with HER2+ metastatic BC who had progressed during or after treatment with trastuzumab and a taxane and were randomly assigned to receive trastuzumab deruxtecan or trastuzumab emtansine.
Disclosures: This study was funded by Daiichi Sankyo and AstraZeneca. Four authors declared being employees or stockholders of Daiichi Sankyo, and the other authors reported ties with various sources, including Daiichi Sankyo and AstraZeneca.
Source: Hurvitz SA et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2022 (Dec 7). Doi: 10.1016/S0140-6736(22)02420-5